These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28320590)

  • 1. MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice.
    Davtyan H; Chen WW; Zagorski K; Davis J; Petrushina I; Kazarian K; Cribbs DH; Agadjanyan MG; Blurton-Jones M; Ghochikyan A
    Vaccine; 2017 Apr; 35(16):2015-2024. PubMed ID: 28320590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology.
    Joly-Amado A; Davtyan H; Serraneau K; Jules P; Zitnyar A; Pressman E; Zagorski K; Antonyan T; Hovakimyan A; Paek HJ; Gordon MN; Cribbs DH; Petrovsky N; Agadjanyan MG; Ghochikyan A; Morgan D
    Neurobiol Dis; 2020 Feb; 134():104636. PubMed ID: 31629891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice.
    Davtyan H; Hovakimyan A; Kiani Shabestari S; Antonyan T; Coburn MA; Zagorski K; Chailyan G; Petrushina I; Svystun O; Danhash E; Petrovsky N; Cribbs DH; Agadjanyan MG; Blurton-Jones M; Ghochikyan A
    Alzheimers Res Ther; 2019 Dec; 11(1):107. PubMed ID: 31847886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates.
    Davtyan H; Ghochikyan A; Petrushina I; Hovakimyan A; Davtyan A; Cribbs DH; Agadjanyan MG
    Alzheimers Dement; 2014 May; 10(3):271-83. PubMed ID: 24560029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules.
    Davtyan H; Zagorski K; Rajapaksha H; Hovakimyan A; Davtyan A; Petrushina I; Kazarian K; Cribbs DH; Petrovsky N; Agadjanyan MG; Ghochikyan A
    Sci Rep; 2016 Jul; 6():28912. PubMed ID: 27363809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active full-length DNA Aβ
    Rosenberg RN; Fu M; Lambracht-Washington D
    Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.
    Troquier L; Caillierez R; Burnouf S; Fernandez-Gomez FJ; Grosjean ME; Zommer N; Sergeant N; Schraen-Maschke S; Blum D; Buee L
    Curr Alzheimer Res; 2012 May; 9(4):397-405. PubMed ID: 22272619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice.
    Hovakimyan A; Antonyan T; Shabestari SK; Svystun O; Chailyan G; Coburn MA; Carlen-Jones W; Petrushina I; Chadarevian JP; Zagorski K; Petrovsky N; Cribbs DH; Agadjanyan MG; Ghochikyan A; Davtyan H
    Sci Rep; 2019 Oct; 9(1):15455. PubMed ID: 31664089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis.
    Selenica ML; Davtyan H; Housley SB; Blair LJ; Gillies A; Nordhues BA; Zhang B; Liu J; Gestwicki JE; Lee DC; Gordon MN; Morgan D; Dickey CA
    J Neuroinflammation; 2014 Sep; 11():152. PubMed ID: 25183004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia.
    Ji M; Xie XX; Liu DQ; Yu XL; Zhang Y; Zhang LX; Wang SW; Huang YR; Liu RT
    Alzheimers Res Ther; 2018 Jun; 10(1):55. PubMed ID: 29914543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MultiTEP platform-based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency.
    Davtyan H; Zagorski K; Petrushina I; Kazarian K; Goldberg NRS; Petrosyan J; Blurton-Jones M; Masliah E; Cribbs DH; Agadjanyan MG; Ghochikyan A
    Neurobiol Aging; 2017 Nov; 59():156-170. PubMed ID: 28870518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial.
    Davtyan H; Ghochikyan A; Petrushina I; Hovakimyan A; Davtyan A; Poghosyan A; Marleau AM; Movsesyan N; Kiyatkin A; Rasool S; Larsen AK; Madsen PJ; Wegener KM; Ditlevsen DK; Cribbs DH; Pedersen LO; Agadjanyan MG
    J Neurosci; 2013 Mar; 33(11):4923-34. PubMed ID: 23486963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery of a DNA vaccine for Alzheimer's disease by electroporation versus gene gun generates potent and similar immune responses.
    Davtyan H; Ghochikyan A; Movsesyan N; Ellefsen B; Petrushina I; Cribbs DH; Hannaman D; Evans CF; Agadjanyan MG
    Neurodegener Dis; 2012; 10(1-4):261-4. PubMed ID: 22301697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease.
    Qu B; Rosenberg RN; Li L; Boyer PJ; Johnston SA
    Arch Neurol; 2004 Dec; 61(12):1859-64. PubMed ID: 15596606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for Alzheimer's disease: DNA- and protein-based epitope vaccines.
    Davtyan H; Petrushina I; Ghochikyan A
    Methods Mol Biol; 2014; 1143():259-81. PubMed ID: 24715293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pentavalent peptide vaccine elicits Aβ and tau antibodies with prophylactic activity in an Alzheimer's disease mouse model.
    Song Y; Dai CL; Shinohara M; Chyn Tung Y; Zhou S; Huang WC; Seffouh A; Luo Y; Willadsen M; Jiao Y; Morishima M; Saito Y; Koh SH; Ortega J; Gong CX; Lovell JF
    Brain Behav Immun; 2024 Nov; 122():185-201. PubMed ID: 39142420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits.
    Ghochikyan A; Davtyan H; Petrushina I; Hovakimyan A; Movsesyan N; Davtyan A; Kiyatkin A; Cribbs DH; Agadjanyan MG
    Hum Vaccin Immunother; 2013 May; 9(5):1002-10. PubMed ID: 23399748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease.
    Petrushina I; Davtyan H; Hovakimyan A; Davtyan A; Passos GF; Cribbs DH; Ghochikyan A; Agadjanyan MG
    Mol Ther; 2017 Jan; 25(1):153-164. PubMed ID: 28129111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics.
    Rosseels J; Van den Brande J; Violet M; Jacobs D; Grognet P; Lopez J; Huvent I; Caldara M; Swinnen E; Papegaey A; Caillierez R; Buée-Scherrer V; Engelborghs S; Lippens G; Colin M; Buée L; Galas MC; Vanmechelen E; Winderickx J
    J Biol Chem; 2015 Feb; 290(7):4059-74. PubMed ID: 25540200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody.
    Albert M; Mairet-Coello G; Danis C; Lieger S; Caillierez R; Carrier S; Skrobala E; Landrieu I; Michel A; Schmitt M; Citron M; Downey P; Courade JP; Buée L; Colin M
    Brain; 2019 Jun; 142(6):1736-1750. PubMed ID: 31038156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.